TREATMENT OF HIGH-GRADE NON-HODGKINS-LYMP HOMAS WITH SHORT INTENSIVE CHEMOTHERAPY (MACOP-B)

We present our results of a MACOP-B regimen in a series of 46 patients with high-grade NHL. The complete remission rate was 74%for patients with advanced stage disease. The excellent tolerance allowed this regi men to be given on an outpatient basis in the majority of cases. The m edian follow-up for the living patients is 28 months. Although some pa tients received additional treatment that could influence the results, the predicted DFS (disease-free survival) at 45 months of 57% compare s favorably with the best results published so far with more toxic reg imens.